9 research outputs found
The correlation between VWF antigen and the CCT of fellow eyes at 1 month after anti-VEGF treatment.
CCT, central choroidal thickness; RVO, retinal vein occlusion.</p
The correlation between VWF antigen and parameters (BCVA, CRT, and CCT) at baseline.
In each graph, the horizontal axis presents the VWF antigen (%). BCVA, best-corrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness; RVO, retinal vein occlusion.</p
Correlations between VWF antigen and parameters (BCVA, CRT, and CCT) at 1 month after anti-VEGF treatment.
In each graph, the horizontal axis presents the VWF antigen (%). BCVA, best-corrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness; RVO, retinal vein occlusion.</p
The correlation between VWF antigen and the CCT of fellow eyes at baseline.
CCT, central choroidal thickness; RVO, retinal vein occlusion.</p
Alterations of clinical data in patients with RVO by treatment.
Alterations of clinical data in patients with RVO by treatment.</p
Alterations of VWF antigen after anti-VEGF treatment.
Each of the values above the graph presents the median with the interquartile range. *< 0.05, **< 0.01. RVO, retinal vein occlusion.</p
Alterations of VWF antigen in patients with branch RVO according to the administered drug.
Each of the values above the graph presents the median with the interquartile range. *< 0.05, **< 0.01. RVO, retinal vein occlusion.</p
Basic characteristics of RVO patients and controls.
Basic characteristics of RVO patients and controls.</p
Basic characteristics of patients with RVO classified according to anti-VEGF drugs.
Basic characteristics of patients with RVO classified according to anti-VEGF drugs.</p